Investigational Drug Information for CC-220
✉ Email this page to a colleague
What is the development status for investigational drug CC-220?
CC-220 is an investigational drug.
There have been 26 clinical trials for CC-220.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 15th 2023.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.
There are twenty-nine US patents protecting this investigational drug and two hundred and eighty international patents.
Summary for CC-220
| US Patents | 29 |
| International Patents | 280 |
| US Patent Applications | 131 |
| WIPO Patent Applications | 71 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 2 (2023-06-15) |
| Vendors | 39 |
Recent Clinical Trials for CC-220
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Bristol-Myers Squibb | Phase 3 |
| A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants | Celgene | Phase 1 |
| A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants | Bristol-Myers Squibb | Phase 1 |
Clinical Trial Summary for CC-220
Top disease conditions for CC-220
Top clinical trial sponsors for CC-220
US Patents for CC-220
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CC-220 | ⤷ Try a Trial | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | Celgene Corporation (Summit, NJ) | ⤷ Try a Trial |
| CC-220 | ⤷ Try a Trial | Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione | Celgene Corporation (Summit, NJ) | ⤷ Try a Trial |
| CC-220 | ⤷ Try a Trial | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast | Celgene Corporation (Summit, NJ) | ⤷ Try a Trial |
| CC-220 | ⤷ Try a Trial | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | Celgene Corporation (Summit, NJ) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CC-220
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CC-220 | Australia | AU2015305449 | 2034-08-22 | ⤷ Try a Trial |
| CC-220 | Australia | AU2021209158 | 2034-08-22 | ⤷ Try a Trial |
| CC-220 | Brazil | BR112017003620 | 2034-08-22 | ⤷ Try a Trial |
| CC-220 | Canada | CA2958867 | 2034-08-22 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
